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Abstract: We aimed at evaluating the characteristics of HIV-1 molecular transmission clusters 
(MTCs) among natives and migrants living in Italy, diagnosed between 1998 and 2018. Phylogenetic 
analyses were performed on HIV-1 polymerase (pol) sequences to characterise subtypes and identify 
MTCs, divided into small (SMTCs, 2–3 sequences), medium (MMTCs, 4–9 sequences) and large 
(LMTCs, ≥10 sequences). Among 3499 drug-naïve individuals enrolled in the Italian Cohort Naive 
Antiretroviral (ICONA) cohort (2804 natives; 695 migrants), 726 (20.8%; 644 natives, 82 migrants) 
were involved in 228 MTCs (6 LMTCs, 36 MMTCs, 186 SMTCs). Migrants contributed 14.4% to 
SMTCs, 7.6% to MMTCs and 7.1% to LMTCs, respectively. HIV-1 non-B subtypes were found in 51 
MTCs; noteworthy was that non-B infections involved in MTCs were more commonly found in 
natives (n = 47) than in migrants (n = 4). Factors such as Italian origin, being men who have sex with 
men (MSM), younger age, more recent diagnosis and a higher CD4 count were significantly 
associated with MTCs. Our findings show that HIV-1 clustering transmission among newly 
diagnosed individuals living in Italy is prevalently driven by natives, mainly MSM, with a more 
recent diagnosis and frequently infected with HIV-1 non-B subtypes. These results can contribute 
to monitoring of the HIV epidemic and guiding the public health response to prevent new HIV 
infections. 
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1. Introduction 
Although HIV-1 is preventable through effective public health measures, substantial HIV 
transmission continues to occur worldwide. In 2018, 1.7 million HIV-1 newly infected individuals 
were reported [1]. In particular, 141,552 newly diagnosed HIV infections were reported in 50 of the 
53 countries in the European Region of the World Health Organization (WHO) [2], while 2847 new 
cases were reported in Italy [3]. 
Among the HIV-1-diagnosed individuals in the EU/EEA in 2018, 42% were migrants, defined as 
originating from outside of the country in which they were diagnosed [2]. In Italy, migrants 
accounted for nearly 30% of all newly diagnosed HIV infections in recent years [2,3]. As a 
consequence of the high percentage of migrants in several European countries including Italy, the 
prevalence of numerous HIV-1 non-B subtypes and circulating recombinant forms (CRFs) has rapidly 
increased in several previously B-restricted areas [4–9]. However, the increasing prevalence of non-
B subtypes is only partially due to migrants, since a substantial amount of such increase is attributable 
to the European-born population, including Italians [4,5,7–10]. 
A considerable proportion of the new HIV diagnoses is involved in well-defined clusters 
prevalently characterized by high-risk sexual behaviours [6,8,11–14]. Accurate identification of these 
transmission clusters and an understanding of HIV-transmission dynamics are very important to 
efficiently target public health interventions. In this context, phylogenetic analysis represents one of 
the most important strategies to better describe and monitor the local HIV epidemics. When 
combined with epidemiological and clinical data, the results of such analysis can be of public health 
relevance, for example by identifying how virus lineages are restricted to, or mix among, different 
demographic and behavioural subgroups [15,16]. 
The aim of this study was to evaluate molecular transmission clusters (MTCs) among native and 
foreign individuals living in Italy diagnosed between 1998 and 2018. Characteristics and drivers of 
the HIV-1 epidemic in Italy were also evaluated by combining MTCs analysis with demographic, 
epidemiological and laboratory data. 
2. Materials and Methods 
2.1. Cohort Description 
The Italian Cohort Naive Antiretroviral (ICONA) Foundation Study is a multi-centre 
prospective observational cohort of HIV-1-infected patients, which was set up in 1997 [17]. Eligible 
patients are those starting combined antiretroviral therapy when they are naive to antiretrovirals, 
regardless of the reason for which they had never been previously treated and of the stage of their 
disease. All patients sign a consent form to participate in ICONA, in accordance with the ethical 
standards of the committee on human experimentation and the Helsinki Declaration (1983 revision). 
Demographic, clinical and laboratory data and information on therapy are collected for all 
participants and recorded using electronic data collection; sensitive data are collected only in an 
anonymous format. Subjects enrolled in the ICONA cohort are broadly representative of the Italian 
HIV-diagnosed population [18]. 
2.2. Study Population 
For this specific study, 3499 newly diagnosed patients enrolled in the ICONA cohort during the 
period between 1998 and 2018, for whom an HIV-1 pol sequence was available at the time of the 
diagnosis, were considered for the analysis. Individuals born in a country other than Italy were 
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classified as migrants. Pol sequences (containing the full-length protease (PR) and the first 240/335 
reverse transcriptase (RT) codons) were produced from plasma samples through the classical Sanger 
sequencing performed according to the protocols used at the laboratories at each Clinical Center 
contributing to the cohort. 
2.3. Phylogenetic Analyses 
Molecular phylogeny was used to determine both HIV-1 subtype for each sequence, as 
previously described [19], and for the cluster analysis. MTCs were first deduced using the HIV-
TRACE (Transmission Cluster Engine) web tool [20,21]. Pairwise genetic distances were obtained 
using HIV-TRACE under the Tamura-Nei 93 (TN93) nucleotide substitution model. This is the most 
general nucleotide substitution model for which distances can be estimated directly from counts of 
nucleotide pairs in aligned sequences [21]. Putative transmission links were inferred when two 
sequences had TN93 genetic distance ≤0.010 substitutions/site. This stringent genetic distance 
threshold has been chosen according to the suggestions by Wertheim and colleagues [22], based on 
the consideration that within a single person, HIV pol sequences tend not to diverge more than 0.01 
substitutions/site from the baseline sequence in the first 10 years of infection [23], with the total 
sequence divergence tending to be less than 0.02 substitutions/site [24]. Therefore, one would expect 
a meaningful epidemiologically genetic distance threshold for identifying transmission partners to 
fall between 0.01 and 0.02 substitutions/site. 
To avoid the influence of convergence evolution at antiretroviral drug resistance mutations, 
sequences were stripped at positions related to drug resistance. 
The robustness of the MTCs was further tested using the maximum likelihood (ML) method and 
a Bayesian analysis. MTCs observed by HIV-TRACE analysis were not considered if not retrieved by 
ML and/or Bayesian phylogenetic analysis. The ML tree was inferred as previously described, using 
the MEGA version 6.06 software [25]. MTCs were recognised by bootstrap values >90% and a <0.015 
average genetic distance. Finally, the Bayesian phylogenetic tree was reconstructed with MrBayes 
version 3.2.2, using a GTR + I + Г5. The Monte Carlo Markov Chain search was run for 5 × 106 
generations, with the trees sampled every 100th generation (with a burn-in of 50%) [26]. Statistical 
support was obtained by calculating the posterior probability of each monophyletic clade, and a 
posterior consensus tree was generated after 50% burn-in. Clades were considered epidemiological 
clusters only if a posterior probability of ≥0.90 was inferred. 
MTCs were then divided into small clusters (SMTCs, 2–3 sequences), medium clusters (MMTCs, 
4–9 sequences) and large clusters (LMTCs, ≥10 sequences). 
2.4. Evaluation of HIV-1 Transmitted Drug Resistance 
Transmitted drug resistance (TDR) was evaluated by considering the WHO 2009 list [27] with 
the additional RT mutations K65E/N, E138A/G/K/Q/R, V179L, G190Q, T215N, H221Y, F227C and 
M230I, reported in the International AIDS Society list [28] and/or the HIVdb V.8.9-1 
(https://hivdb.stanford.edu/, last updated 25/10/2019). HIV-1 strains were defined as resistant if 
carrying at least one TDR mutation. 
2.5. Statistical Analysis 
Comparisons between patients belonging or not to clusters were evaluated using the Mann–
Whitney test for quantitative variables and Chi-square or Fisher’s exact test for categorical variables. 
Factors potentially associated with MTCs were evaluated using multivariable logistic regression 
analysis. In particular, the following factors were included in the model: gender, mode of HIV 
transmission, nation of birth, level of education, type of employment, plasma HIV RNA and CD4 cell 
count at sequencing and calendar year of HIV diagnosis. All analyses were performed using STATA 
version 15.1 (StataCorp College Station, Texas, USA). p-values <0.05 were considered as statistically 
significant.  
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2.6. Sequences Deposited to GenBank 
All 726 sequences involved in the 228 molecular transmission clusters have been deposited into 
GenBank (accession numbers: MT787750-MT788351; MT788352-MT788382; MT788383-MT788475). 
All other sequences are available on request. 
3. Results 
3.1. Patients’ Characteristics 
A total of 3499 HIV-1 newly diagnosed participants in the ICONA cohort from 1997 through 
2018 were included (Table 1). The majority of these individuals (2872; 82.1%) were male, Italian (2804; 
80.1%) and MSM (1789; 51.1%). Migrants accounted for 19.9%, had lived in Italy for a median 
(interquartile range, IQR) of 5 (1–9) years and were represented mainly by subjects from Central and 
South America (241, 6.9%) and Africa (219, 6.3%), followed by Europe (187, 5.3%), Asia (38, 1.1%) and 
other areas (10, 0.3%) (Table 1 and Table S1). Phylogenetic analysis revealed that most individuals (n 
= 2556; 73.1%) were infected with B subtype, followed by CRF02_AG (187; 5.3%), F1 (179; 5.1%), C 
(148; 4.2%), A1 (104; 3.0%), CRF60_BC (64; 51.8%) and other subtypes/CRFs (261; 7.5%). 
The overall prevalence of TDR was 14.3% (n = 501), mainly imputable to resistance associated 
with non-nucleoside RT inhibitors (NNRTI) (9.6%). 
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Table 1. Patient’s characteristics and factors associated with HIV-1 molecular transmission clusters. 
Variables 
Overall 
Out of 
Cluster 
In Cluster 
p-
valuea 
Adjusted Modelb 
n = 3499 2773 (79.3%) 
726 
(20.7%) 
OR (95% CI) 
p-
value 
Male gender, n (%) 
2872 
(82.1%) 
2187 (78.9%) 
685 
(94.3%) 
<0.001 - - - 
Age, years, median (IQR) 37 (30–45) 38 (31–46) 32 (27–40) <0.001 
0.6
5 
0.59–0.72 <0.001 
Mode of HIV transmission, n 
(%) 
       
F heterosexual 553 (15.8%) 513 (18.5%) 40 (5.5%) <0.001 
1.0
0 
- - 
F IVDU 32 (0.9%) 31 (1.1%) 1 (0.1%)  
0.4
9 
0.06–3.80 0.497 
M heterosexual 713 (20.4%) 628 (22.7%) 85 (11.7%)  1.8
2 
1.19–2.78 0.006 
M IVDU 161 (4.6%) 145 (5.2%) 16 (2.2%)  
1.5
2 
0.80–2.90 0.204 
MSM 
1789 
(51.1%) 
1247 (45.0%) 
550 
(75.8%) 
 3.4
6 
2.39–5.03 <0.001 
Other/unknown 251 (7.2%) 209 (7.5%) 34 (4.7%)  
2.7
3 
1.66–4.48 <0.001 
Nation of birth, n (%)        
Italy 
2804 
(80.1%) 
2160 (77.8%) 
644 
(88.7%) 
<0.001 
1.0
0 
- - 
Africa 219 (6.3%) 212 (7.7%) 7 (0.9%)  
0.1
8 
0.08–0.39 <0.001 
Central and South America 241 (6.9%) 201 (7.3%) 40 (5.5%)  
0.4
9 
0.33–0.71 0.001 
Europe 187 (5.3%) 159 (5.7%) 28 (3.9%)  
0.2
9 
0.08–0.97 0.045 
Asia 38 (1.1%) 35 (1.3%) 3 (0.4%)  
0.6
2 
0.40–0.97 0.035 
Other 10 (0.3%) 6 (0.2%) 4 (0.6%)  
2.6
1 
0.62–
10.97 
0.189 
Education, n (%)        
Primary school 169 (4.8%) 158 (5.7%) 11 (1.5%) <0.001 
0.8
7 
0.45–1.71 0.691 
Secondary school 585 (16.7%) 505 (18.2%) 80 (11.0%)  
0.9
1 
0.68–1.21 0.518 
College/University 
1762 
(50.4%) 
1329 (47.9%) 
433 
(59.6%) 
 1.0
0 
-  
Unknown 983 (28.1%) 781 (28.2%) 
202 
(27.8%) 
 1.0
3 
0.83–1.28 0.773 
Employment, n (%)        
Employed 
1476 
(42.2%) 
1148 (41.4%) 
328 
(45.2%) 
<0.001 
1.0
0 
- - 
Unemployed 461 (13.2%) 389 (14.0%) 72 (9.9%)  
0.9
1 
0.67–1.25 0.565 
Self-employed 526 (15.0%) 413 (14.9%) 113 (15.6)  
0.9
7 
0.75–1.26 0.840 
Student 146 (4.2%) 93 (3.4%) 53 (7.3%)  
0.8
3 
0.56–1.24 0.360 
Housewife 94 (2.7%) 88 (3.2%) 6 (0.8%)  
1.1
8 
0.47–2.94 0.723 
Other 278 (7.9%) 244 (8.8%) 34 (4.7%)  
0.6
9 
0.46–1.05 0.083 
Unknown 518 (14.8%) 398 (14.3%) 
120 
(16.5%) 
 0.9
9 
0.75–1.30 0.929 
HIV RNA, copies/mL, n (%)        
<1000 122 (3.5%) 99 (3.6%) 23 (3.2%) 0.005 
0.6
6 
0.39–1.12 0.127 
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1000–10,000 559 (16.0%) 445 (16.1%) 
114 
(15.7%) 
 0.8
1 
0.61–1.08 0.147 
10,000–100,000 1470 
(42.0%) 
1126 (40.6%) 344 
(47.4%) 
 0.9
4 
0.75–1.17 0.562 
>100,000 
1118 
(32.0%) 
905 (32.6%) 
213 
(29.3%) 
 1.0
0 
-  
Unknown 230 (6.6%) 198 (7.1%) 32 (4.4%)  
0.7
6 
0.38–1.55 0.451 
CD4, cells/mm3, n (%)        
≤200 791 (22.6%) 721 (26.0%) 70 (9.6%) <0.001 
1.0
0 
- - 
201–500 
1485 
(42.4%) 
1165 (42.0%) 
320 
(44.1%) 
 2.2
2 
1.64–2.99 <0.001 
>500 
1003 
(28.7%) 
703 (25.4%) 
300 
(41.3%) 
 3.0
1 
2.20–4.13 <0.001 
Unknown 220 (6.3%) 184 (6.6%) 36 (5.0%)  
1.9
0 
0.93–3.90 0.078 
Year of diagnosis,  
median (IQR) 
2011  
(2008–2014) 
2011  
(2007–2014) 
2012  
(2009–
2014) 
<0.001 
1.0
9 
1.06–1.11 <0.001 
Subtype, n (%)        
A1 104 (3.0%) 85 (3.1%) 19 (2.6%) <0.001 - - - 
B 
2556 
(73.1%) 
2038 (73.5%) 
518 
(71.4%) 
 - - - 
C 148 (4.2%) 119 (4.3%) 29 (4.0%)  - - - 
CRF02_AG 187 (5.3%) 141 (5.1%) 46 (6.3%)  - - - 
CRF60_BC 64 (1.8%) 12 (0.4%) 52 (7.2%)  - - - 
F1 179 (5.1%) 157 (5.7%) 22 (3.0%)  - - - 
Other 261 (7.5%) 221 (8.0%) 40(5.5%)  - - - 
Transmitted drug resistance, n 
(%) 
       
Any drug class 501 (14.3) 420 (15.1) 81 (11.2) 0.006 - - - 
NNRTI 335 (9.6) 281 (10.1) 54 (7.4) 0.028 - - - 
NRTI 150 (4.3) 134 (4.8) 16 (2.2) 0.002 - - - 
PI 66 (1.9) 53 (1.9) 13 (1.8) 0.832 - - - 
a By Mann–Whitney test (for quantitative variables) and χ2 test or Fisher’s exact test (for categorical 
variables), as appropriate. p-values <0.05 were considered statistically significant and were reported 
in bold. bAdjusted for: Sex, age, mode of HIV transmission, nation of birth, education, employment, 
plasma HIV-RNA, CD4 cell count, year of diagnosis. Variables that were significant in univariable 
analysis (p < 0.05) were considered for the multivariable model. F: female; IVDU: intravenous drug 
user; M: male; MSM: men who have sex with men; NNRTI: non-nucleoside reverse transcriptase 
inhibitor; NRTI: nucleos(t)ide reverse transcriptase inhibitor; PI: protease inhibitor. 
3.2. Cluster Identification 
Overall, 228 MTCs including 2–52 individuals were identified by both HIV-TRACE and 
phylogenetic analyses (Figures 1, S1 and S2). No differences between the two methods were 
identified. MTCs involved 726 individuals (20.7%; 644 natives and 82 migrants). Of the 228 MTCs 
identified, 186 were SMTCs (2–3 sequences) involving 402 individuals (11.5%), 36 MMTCs (4–9 
sequences) involving 184 individuals (5.3%) and 6 LMTCs (≥10 sequences) involving 140 individuals 
(4.0%) (Table 2). The presence of both natives and migrants was found in 66.7% of LMTCs, 33.3% of 
MMTCs and 23.1% of SMTCs. Migrants were involved mainly in SMTCs (n = 58; 70.7%). Individuals 
infected with HIV-1 B subtype in MTCs were present with a higher prevalence than those infected 
with non-B subtype (71.4% vs. 28.6%). Individuals infected with non-B subtypes were part of 51 
MTCs (22.4%) (SMTCs: 37; MMTCs: 11; LMTCs: 3; Table 2); only four of these MTCs were entirely 
composed of migrants (7.8%). 
By analyzing the date of diagnosis of individuals involved in MTCs, it was found that before 
2010 the proportion of individuals involved in the clusters was 34.6% (n = 251: SMTCs, n = 156, 38.8%; 
MMTCs/LMTCs = 95, 29.3%). Only a few individuals were involved in MTCs before 2007 (n = 38, 
5.2%: SMTCS, n = 30, 7.5%; MMTCs/LMTCs = 8, 2.5%). Starting from 2011, the proportion of 
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individuals involved in MTCs was 65.4% (n = 475: SMTCs, n = 246, 61.2%; MMTCs/LMTCs = 229, 
70.7%). Migrants, on the other hand, were only involved in MTCs from 2007. In particular, the 
proportion of migrants in MTCs between 2007 and 2010 was overall 26.8% (n = 22: SMTCs, n = 18, 
31.0%; MMTCs/LMTCs = 4, 16.7%), whereas after 2011 the proportion of migrants in MTCs was 73.2% 
(n = 60: SMTCs, n = 40, 69.0%; MMTCs/LMTCs = 20, 83.3%). 
Regarding TDR, 81 (11.2%) individuals involved in MTCs carried a resistant virus. This 
proportion was lower compared to that found in individuals out of MTCs (15.1%, p = 0.006). 
Individuals with a resistant virus were involved in 36 SMTCs (29 B, 2 C, 2 CRF01_AE, 1 CRF02_AG, 
1 CRF24_BG, 1 F1), five MMTCs (three B, one CRF02_AG, and one CRF12_BF) and one LMTC 
(CRF60_BC). 
 
Figure 1. Clusters’ population by HIV-TRACE. The coloured geometric shapes identify the nationality 
and risk factors of the 3499 individuals involved in the study. Shapes without connections represent 
individuals not involved in molecular transmission clusters. Shapes connected with lines represent 
individuals involved in molecular transmission clusters. 
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Table 2. Characteristics of molecular transmission clusters found among 3499 drug-naïve individuals 
living in Italy. 
Cluster’s Characteristics 
Small Clusters Medium 
Clusters 
 
n = 36 
Large 
Clusters 
 
n = 6 
Overall 
Clusters of 2 
Persons 
Clusters of 3 
Persons 
n = 186 n = 156 n = 30 
Sampling interval (min–max) 2–3 - - 4–9 10–52 
Age interval (min–max) 19–65 19–65 20–56 18–53 18–58 
Mode of HIV transmission, n (%)           
Only MSM 101 (54.3%) 82 (52.5%) 19 (63.3%) 18 (50.0%) - 
Only heterosexual (F+M) 13 (7.0%) 13 (8.3%) - - - 
Only heterosexual (only F) 4 (2.2%) 4 (2.6%) - - - 
Only heterosexual (only M) 5 (2.7%) 5 (3.2%) - - - 
Only IVDU (F+M) 1 (0.5%) 1 (0.6%) - - - 
Only IVDU (only M) 2 (1.1%) 2 (1.3%) - - - 
Mixed (F+M) 18 (9.7%) 9 (5.8%) 4 (13.3%) 4 (11.1%) 1 (16.7%) 
Mixed (only M) 42 (22.5%) 40 (25.5%) 7 (23.3%) 14 (38.9%) 5 (83.3%) 
Nationality, n (%)           
Only Italians 137 73.7%) 122 (78.2%) 15 (50.0%) 24 (66.7%) 2 (33.3%) 
Italians and migrants 43 (23.1%) 28 (18.0%) 15 (50.0%) 12 (33.3%) 4 (66.7%) 
Only migrants  6 (3.2%) 6 (3.8%) - - - 
Subtype, n (%)           
A1 3 (1.6%) 2 (1.2%) 1 (3.3%) 2 (5.6%) - 
B 149 (80.1%) 125 (80.1%) 24 (80.0%) 25 (69.3%) 3 (50.0%) 
C 5 (2.7%) 4 (2.6%) 1 (3.3%) 2 (5.6%) 1 (16.7%) 
CRF02_AG 5 (2.7%) 3 (1.9%) 2 (6.7%) 5 (13.9%) 1 (16.7%) 
CRF60_BC - - - - 1 (16.7%) 
F1 11 (5.9%) 11 (7.1%) - - - 
Other 13 (7.0%) 11 (7.1%) 2 (6.7%) 2 (5.6%) - 
Resistance, n (%)           
None 150 (80.7) 123 (78.8) 27 (90.0) 31 (86.1) 5 (83.3) 
Any drug class 36 (19.3) 33 (21.2) 3 (10.0) 5 (13.9) 1 (16.7) 
NNRTI 24 (12.9) 22 (14.1) 2 (6.7) 3 (8.3) 1 (16.7) 
NRTI 6 (3.2) 5 (3.2) 1 (3.3) 1 (2.8) 0 (0.0) 
PI 7 (3.8) 7 (4.5) 0 (0.0) 1 (2.8) 0 (0.0) 
IVDU: intravenous drug user; MSM: men who have sex with men; NNRTI: non-nucleoside reverse 
transcriptase inhibitor; NRTI: nucleos(t)ide reverse transcriptase inhibitor; PI: protease inhibitor. 
3.3. Epidemiological Characteristics and Factors Associated with MTCs 
With regard to the characteristics of individuals involved in MTCs in comparison with those out 
of MTCs, male gender (94.3% vs. 78.9%, p < 0.001), being MSM (75.8% vs. 45.0%, p < 0.001) and natives 
(88.7% vs. 77.8%, p < 0.001) were significantly associated with being in MTCs (Table 1). Individuals 
in MTCs were also younger (median (IQR) age: 32 (27–40) vs. 38 (31–46) years, p < 0.001), more 
recently diagnosed (median (IQR) year of diagnosis: 2012 (2009–2014) vs. 2011 (2007–2014), p < 0.001), 
and had higher CD4 cell count on diagnosis (median (IQR) cells/mm3: 459 (322–624) vs. 353 (177–523), 
p < 0.001) in comparison with individuals out of MTCs. Moreover, a lower prevalence of TDR was 
found among individuals in MTCs compared to those out of MTCs (11.2% vs. 15.1%, p < 0.001). 
Multivariable logistic regression confirmed that Italian origin, being MSM, of younger age, a more 
recent diagnosis, and higher CD4 cell count were factors significantly associated with MTCs (Table 
1). 
3.4. Characteristics of the Medium/Large Clusters 
Information of MMTCs (n = 36) and LMTCs (n = 6) is reported in Tables 2 and 3. The majority of 
MTCs were composed only of males (MMTCs: 32/36, 88.9%; LMTCs: 5/6, 83.3%). The most common 
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risk factor was same-gender sex (49.8% of the MSM in the overall MTCs), followed by heterosexual 
contacts (24.8% of the heterosexuals in the overall MTCs). As regards to migrants, they contributed 
7.6% to MMTCs and 7.1% to LMTCs, respectively. The 24 migrants involved in these medium/large 
MTCs were mainly from Central/South America or other European countries (Table 3). 
Some of the individuals involved in these MTCs carried the following pathways of mutations 
associated with drug resistance: I85V in PR (n = 1), and A62V (n = 3), E138A (n = 6) or K101E (n = 5) 
in RT (Table 3). The median genetic distance was ≤0.016 substitution/site in each MTC, highlighting 
the tight correlation among individuals involved in the MTC. 
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Table 3. Clusters characteristics. 
Medium MTCs (4–9 Sequences) 
ID Subtype 
Cluster 
Sizea 
n 
Sampling 
Interval 
Year 
HIV 
Diagnosis 
Interval Year 
Migrantsb  
n (%) 
Migrants’ 
nationality 
n 
Age, Years 
Median 
(IQR) 
Risk Factor  
n 
Genetic 
Distance 
Mean (SE) 
Resistance 
1 B 4 2006–2007 2006–2007 0 (0.0) - 46 (44–46) 4 MSM 0.008 (0.002)  No 
2 B 4 2007–2012 2004–2012 0 (0.0) - 46 (42–50) 1 F Het, 2 M Het, 1 M Unk 0.010 (0.002)  No 
3 B 4 2008–2014 2008–2014 0 (0.0) - 52 (50–53) 4 MSM 0.008 (0.002)  No 
4 B 4 2008–2016 2008–2016 0 (0.0) - 39 (37–41) 3 MSM, 1 M Unk 0.006 (0.002)  No 
5 B 4 2009–2012 2009–2012 0 (0.0) - 54 (51–56) 3 MSM, 1 F Het 0.009 (0.002)  No 
6 B 4 2009–2016 2009–2016 0 (0.0) - 36 (33–41) 3 MSM, 1 M Unk 0.009 (0.002)  Yes (n = 4; RT: E138A) 
7 B 4 2010–2011 2010 1 (25.0) 1 NA 50 (46–52) 4 MSM 0.004 (0.002)  No 
8 B 4 2011–2013 2011–2013 0 (0.0) - 37 (35–38) 4 MSM 0.008 (0.002)  No 
9 B 4 2011–2017 2011–2017 0 (0.0) - 53 (48–56) 4 MSM 0.007 (0.002)  No 
10 B 4 2013–2014 2010–2014 0 (0.0) - 41 (34–48) 4 MSM 0.006 (0.002)  No 
11 B 4 2013–2018 2013–2018 1 (25.0) 1 EE 41 (37–43) 3 MSM, 1 M Het 0.008 (0.002)  No 
12 B 4 2016 2015–2016 0 (0.0) - 38 (28–49) 4 MSM 0.004 (0.001)  Yes (n = 1; PR: I85V) 
13 B 5 2007–2012 2007–2011 1 (20.0) 1 NA 38 (37–45) 5 MSM 0.006 (0.001)  No 
14 B 5 2008–2014 2008–2014 0 (0.0) - 36 (36–37) 5 MSM 0.011 (0.002)  No 
15 B 5 2010–2012 2009–2012 2 (40.0) 1 CA, 1 EE 41 (37–43) 5 MSM 0.008 (0.002)  No 
16 B 5 2011–2017 2008–2017 0 (0.0) - 38 (37–45) 4 MSM, 1 M Het 0.009 (0.002)  No 
17 B 5 2011–2017 2011–2017 0 (0.0) - 33 (32–35) 5 MSM 0.009 (0.002)  Yes (n = 5; RT: K101E) 
18 B 5 2013–2018 2013–2018 1 (20.0) 1 SA 38 (36–43) 3 MSM, 2 M Het 0.011 (0.002)  No 
19 B 6 2007–2011 2006–2011 0 (0.0) - 41 (36–48) 6 MSM 0.010 (0.002)  No 
20 B 6 2007–2011 2007–2011 0 (0.0) - 42 (37–45) 5 MSM, 1 M Unk 0.011 (0.002)  No 
21 B 6 2010–2014 2010–2014 0 (0.0) - 37 (35–43) 5 MSM, 1 M Het 0.011 (0.002)  No 
22 B 7 2006–2016 2006–2009 1 (14.3) 1 SA 43 (39–48) 7 MSM 0.010 (0.002)  No 
23 B 7 2009–2014 2008–2014 2 (28.6) 2 SA 51 (40–53) 7 MSM 0.011 (0.002)  No 
24 B 9 2010–2016 2010–2014 0 (0.0) - 40 (34–52) 7 MSM, 1 M Het, 1 M Unk 0.009 (0.002)  No 
25 B 9 2017–2018 2017–2018 0 (0.0) - 34 (31–41) 8 MSM, 1 M Unk 0.006 (0.001)  No 
26 A1 4 2013–2015 2013–2015 0 (0.0) - 47 (45–50) 4 MSM 0.010 (0.002)  No 
27 A1 8 2014–2016 2013–2016 1 (12.5) 1 WE 37 (33–39) 8 MSM 0.008 (0.002)  No 
28 C 4 2007–2011 2006–2011 1 (25.0) 1 SA 46 (44–47) 3 MSM, 1 M Het 0.007 (0.002)  No 
29 C 4 2012–2016 2012–2016 0 (0.0) - 50 (45–52) 3 M Het, 1 M MSM 0.009 (0.002)  No 
30 CRF02_AG 4 2009–2013 2009–2012 0 (0.0) - 35 (35–37) 4 MSM 0.007 (0.002)  No 
31 CRF02_AG 4 2009–2013 2009–2013 0 (0.0) - 38 (38–40) 2 MSM, 1 F Het, 1 M Unk 0.004 (0.001)  No 
32 CRF02_AG 4 2014 2014 1 (25.0) 1 EE 34 (30–39) 3 MSM, 1 M Het 0.009 (0.002)  Yes (n = 1; RT: E138A) 
33 CRF02_AG 5 2013–2014 2012–2014 0 (0.0) - 34 (33–35) 4 MSM, 1 M Unk 0.006 (0.002)  No 
34 CRF02_AG 7 2010–2017 2010–2016 0 (0.0) - 41 (36–51) 6 MSM, 1 M Het 0.005 (0.001)  No 
35 CRF12_BF 5 2014–2015 2013–2015 1 (20.0) 1 SA 34 (27–34) 2 F Het; 2 M Het, 1 M Unk 0.010 (0.002)  Yes (n = 3; RT: A62V) 
36 CRF20_BG 7 2013–2017 2013–2017 1 (14.3) 1 Aus 33 (32–37) 7 MSM 0.005 (0.001)  No 
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Large MTCs (≥10 Sequences) 
1 B 14 2008–2016 2008–2016 0 (0.0) - 40 (34–49) 11 MSM, 2 M Het, 1 M IVDU 0.010 (0.001)  No 
2 B 19 2007–2015 2007–2015 2 (10.5) 1 EE, 1 SA 37 (32–43) 18 MSM, 1 M Unk 0.016 (0.002)  No 
3 B 35 2009–2017 2009–2017 2 (5.7) 1 WE, 1 SA 34 (33–43) 33 MSM, 1 M Het, 1 M Unk 0.013 (0.002)  No 
4 C 10 2011–2016 2011–2016 0 (0.0) - 39 (35–42) 8 MSM, 1 M Het, 1 M Unk 0.009 (0.001)  No 
5 CRF02_AG 10 2006–2016 2006–2016 1 (10.0) 1 CA 42 (35–46) 9 MSM, 1 M Het 0.011 (0.002)  No 
6 CRF60_BC 52 2008–2018 2008–2018 5 (9.6) 4 EE, 1 Unk 34 (31–37) 
41 MSM, 2 F Het, 3 M Het, 6 M 
Unk 
0.012 (0.001)  Yes (n = 1; RT: E138A) 
a Number of individuals involved in a specific MTC. Het: heterosexual; MSM: men who have sex with men; Unk: unknown; PR: protease; RT: reverse transcriptase. 
Aus: Australian, CA: Central American; EE: East European; F: female; M: male; NA: North American; SA: South American; WE: West European. 
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3.5. Characteristics of the Small Clusters 
Focusing attention on the 186 SMTCs, 156 (83.9%) were composed of two persons, and 30 (16.1%) 
of three persons (Table 2). The contribution of females in these SMTCs was minimal (34/402 (8.5%): 
31 in pairs and 3 in MTCs composed of three individuals). Overall, these SMTCs were composed 
mainly of MSM (54.3%). Interestingly, 32.8% included individuals with mixed transmission 
categories, mainly among MSM and heterosexual contacts (19.9%) predominantly found in TCs 
(86.5%) pairs. The great majority of these TCs were exclusively composed of Italians (73.7%), while 
about 23.1% of them were composed of mixed nationality. Only six (3.2%) of the SMTCs were totally 
composed of migrant couples (Table 2) originating from Africa (n = 3), Asia (n = 1), America (n = 1) 
and Eastern Europe (n = 1) (data not shown); four of them (67%) were composed of heterosexual 
individuals that came from the same country in Africa (n = 3) and Asia (n = 1) (Figure 1), while the 
other two were composed of MSM. 
Regarding TDR, 66 individuals (involved in 36 SMTCs, 19.3%) carried drug resistance 
mutations. 
In particular, seven SMTCs (12 individuals) carried only PI resistance mutations (K23I, M46I/L, 
F53Y, I85V, L90M); twenty-four SMTCs (43 individuals) carried NNRTI resistance mutations (L100I, 
K101E, K103N/S, V106I, E138A/G/K, G190A), alone or in combination with other RTI resistance 
mutations. Specifically, one SMTC, composed of two individuals, carried the combination 
K103N+E138A, and one SMTC had the combination L100I + K103N + L210W + T215D. 
Five SMTCs (11 individuals) carried NRTI resistance mutations (M41L, D67N, L210W, 
T215S/L/D, K219Q), alone or in combination with other NRTI mutations. In particular, the following 
combinations were found in all the individuals involved in the MTCs: M41L+T215L (three 
individuals), D67N+K219Q (two individuals), while one pair was composed of one individual with 
the M41L and one with the M41L+T215D combination. 
4. Discussion 
This study provides molecular evidence of HIV-1 epidemiological clusters circulating in Italy 
among 3499 native and foreign individuals diagnosed between 1998 and 2018 enrolled in the ICONA 
cohort. Around 21% of the overall individuals included in the analysis were involved in clusters. 
Clustering analysis showed the presence of a high number of MTCs; in particular, 228 MTCs 
including 6 LMTCs, 36 MMTCs and 186 SMTCs were identified. 
In general, clustered transmission was prevalently driven by native individuals (644, 88.7%); in 
fact, 222 MTCs (97.4%) were composed mainly of Italian individuals, and more in particular, 157 
MTCs (70.7%) were composed exclusively of Italian persons and 65 MTCs (29.3%) showed an 
intermixing between migrants and Italians. Only six SMTCs of the overall MTCs were composed 
exclusively of a couple of migrant individuals—67% were composed by heterosexual individuals and 
came from the same country in Africa and Asia. This highlights how some migrants probably 
acquired HIV in their home country and how in certain geographical areas the transmission route is 
mainly represented by heterosexual contacts [29]. A minimal contribution of migrants in MTCs was 
also found in Belgium, despite the high prevalence of foreign individuals living in this country [10]. 
In particular, in the Belgian cohort, the percentage of foreign people was much higher than in our 
cohort (53.0% vs. 19.9%). Furthermore, foreign individuals infected with HIV (for example those from 
Europe) might look slightly less actively involved in cluster formation in Italy than in Belgium, 
although both cohorts showed similar tendencies. Despite these differences between the two cohorts, 
overall findings support the fact that clustering is mainly driven by natives. 
Individuals involved in MTCs were younger, mainly male and MSM, with a recent diagnosis 
and higher CD4 count compared to those out of MTCs. These findings are in agreement with several 
studies on transmission clusters from the USA, Asia and Europe [8,10,14,19,30–36] and led us to 
hypothesise that MSM are more aware than others of having both high-risk behaviour and a high 
self-perception of risk for acquiring HIV, and for this reason, they test more frequently than others 
and are thus diagnosed earlier. 
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Even though MSM was the most prevalent risk factor in MTCs, different risk behaviours were 
observed among individuals belonging to the same MTCs. In particular, mixtures of MSM and 
heterosexual contacts were observed in most MTCs. In fact, at least one heterosexual contact was 
observed in 19.9%, 27.8%, and 83.0% of each SMTCs, MMTCs, and LMTCs, respectively. Noteworthy 
was that the majority of MTCs found the number of MSM clearly outweighed the number of 
heterosexuals, and in many, only men were represented. This observation is in line with that reported 
in previous studies and suggests that misreporting of transmission risk may be an important reason 
for the presence of mixed clusters [10,37,38]. The most important reason for misreporting could be 
fear or embarrassment to disclose sex with same-gender sex. Another explanation for the presence of 
mixed transmission risk clusters may be due to the fact that homosexual orientation is frequently 
masked by bisexual behaviours in older individuals, and men who have sex with men and women 
are a potential bridge population for transmitting HIV to heterosexual women [6,10,39,40]. Along the 
same line, intravenous drug users may serve as a go-between risk category. 
Of note, about a quarter of MTCs were characterized by HIV-1 non-B subtypes; in particular, 
50% of LMTCs and 30% of MMTCs were driven by these viral strains. By considering the fact that 
only a small portion of migrants was present in these non-B MTCs, in the most part of cases 
interspersed with natives, this finding confirms the fact that HIV-1 non-B variants have entered and 
are to date circulating in newly diagnosed individuals originating from Italy. This is in line with the 
important increase of non-B pure subtypes and CRFs reported in several European countries during 
the last decade. This increase in non-B subtypes occurred in conjunction with associated 
epidemiological changes, such as (1) increase in immigration and tourism from areas with non-B 
subtypes, (2) travel-associated infections and (3) increased internal circulation in Italy of imported 
subtypes [5,7–10,12,14,41–47]. 
By specifically considering the date of diagnosis, most individuals in MTCs were diagnosed after 
2010, thus suggesting that the expansion of epidemics in Italy seems mainly associated with recent 
MTCs, rather than the growth of older, established ones. This has also been confirmed by 
multivariable logistic regression analysis, showing that a more recent diagnosis is a factor positively 
associated with MTCs. The involvement of migrants in MTCs has a similar temporal trend of the 
overall population. From the public health point of view, all this information is important for 
designing prevention and public health intervention strategies. 
Regarding TDR, 14.3% of the overall individuals harboured a resistant virus, mainly imputable 
to NNRTI resistance mutations. This TDR prevalence is slightly higher than in other studies 
[7,39,46,48] because in the analysis, we considered the E138A mutation, associated with resistance to 
etravirine and rilpivirine [49–52]. In fact, by removing this mutation, the overall prevalence of TDR 
in our study population was found to be 9.8%, similar to that already reported in literature 
[7,10,42,46,48,53], remaining mainly attributed to NNRTI resistance (4.8%). As E138A is a 
polymorphic mutation that ranges in prevalence from about 1% to 5% depending on subtype [54], its 
high prevalence in our population might not necessarily be related to TDR. 
By evaluating the prevalence of TDR in and out of MTCs, similarly to that observed in previous 
studies [8,46], a resistant virus was less frequent among individuals involved in MTCs compared 
with those out (11.2% vs. 15.1%), and this was also confirmed by excluding the E138A mutation (data 
not shown). On the other hand, different results have been found by Verhofstede et al. [10] describing 
a slightly higher TDR prevalence within the clusters. These discrepancies might be explained by 
different characteristics of the study populations analyzed. Resistance to more than one class was 
found only in one SMTCs, where mutations for both NRTIs and NNRTIs were present. By assessing 
TDR prevalence in MTCs according to drug class, we mainly found the mutations associated with 
resistance to NNRTIs K101E and E138A, which are at low fitness cost [55,56]. 
As with any other observational study, our data may have some limitations. Firstly, our study 
population might not be representative of the overall population living in Italy. In particular, it has 
been estimated that to date, migrant individuals with new HIV-1 diagnoses accounted for nearly 30% 
of all the newly diagnosed HIV infections in Italy in recent years [3]. Despite the fact that in the overall 
ICONA cohort this percentage is confirmed [17], in our specific study population, the overall 
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percentage of migrants was lower (around 20%). This is due to the fact that the sequences at diagnosis 
were not available for all the individuals enrolled in the cohort. Thus the contribution of migrants in 
MTCs could be underestimated; in fact, unsampled individuals might limit the correct idea of the 
migrant circulation in our country. However, our results are in line with other previous Italian studies 
in different study populations that showed that the contribution of migrants in the cluster is minimal 
[6,8,46]. 
Moreover, we should take into account that phylogenetic analyses are limited by their inability 
to infer direction of transmission: the absence of the contribution of sequences from drug-treated 
individuals and unsampled individuals might limit correct transmission dynamics. Finally, another 
significant limitation to this study is the lack of information on the country of infection, because these 
are important data to establish the geographical origin of the MTCs. This could explain, for example, 
the presence of couples in our study population composed only of heterosexual individuals of the 
same gender, even though we cannot exclude a misclassification of the risk factor for these cases. 
Nonetheless, the detection of MTCs and the associated demographic and viroimmunological 
parameters can help us to focus proven HIV prevention tools where they are needed most. 
In conclusion, this study shows that HIV-1 newly diagnosed subjects are involved in several 
MTCs in the past two decades in Italy. Clustered transmission, especially for large clusters, is 
prevalently driven by natives, mainly MSM, with a recent diagnosis and frequently infected with 
HIV-1 non-B subtype. Participation of migrants in clustered transmission is rare. 
These results reinforce the fact that phylodynamics represent one of the most important tools to 
better describe and monitor local HIV epidemics, by correlating the genetic relationship of the viruses 
with information on demographics, transmission mode and new infections.  
Overall, our findings can contribute to monitoring of the HIV epidemic and guiding the 
public health response in Italy to prevent new infections. 
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